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Abstract: About one in 15 of the world’s population is chronically infected with either hepatitis virus
B (HBV) or C (HCV), with enormous public health consequences. The metabolic alterations caused
by these infections have never been directly compared and contrasted. We investigated groups
of HBV-positive, HCV-positive, and uninfected healthy controls using gas chromatography-mass
spectrometry analyses of their plasma and urine. A robust regression analysis of the metabolite data
was conducted to reveal correlations between metabolite pairs. Ten metabolite correlations appeared
for HBV plasma and urine, with 18 for HCV plasma and urine, none of which were present in the
controls. Metabolic perturbation networks were constructed, which permitted a differential view
of the HBV- and HCV-infected liver. HBV hepatitis was consistent with enhanced glucose uptake,
glycolysis, and pentose phosphate pathway metabolism, the latter using xylitol and producing
threonic acid, which may also be imported by glucose transporters. HCV hepatitis was consistent
with impaired glucose uptake, glycolysis, and pentose phosphate pathway metabolism, with the
tricarboxylic acid pathway fueled by branched-chain amino acids feeding gluconeogenesis and the
hepatocellular loss of glucose, which most probably contributed to hyperglycemia. It is concluded
that robust regression analyses can uncover metabolic rewiring in disease states.
Keywords: metabolomics; robust regression analysis; metabolic perturbation networks; hepatitis
B virus; hepatitis C virus; glycolysis; gluconeogenesis; pentose phosphate pathway; glucose
transporters; TCA cycle
1. Introduction
Hepatitis B virus (HBV) has been reported to infect some two billion persons, with greater than
350 million chronically infected [1]. In contrast, hepatitis C virus (HCV), which exists as seven variant
genotypes [2], is believed to have infected 185 million persons [3]. The development of hepatocellular
carcinoma (HCC) has a lifetime risk of 20% to 30% for untreated persons chronically infected with HBV,
HCV, or both [4]. In an attempt to understand the mechanisms of infection and the progression of viral
hepatitis to end-stage liver disease, both HBV [5,6] and HCV [5,7] attracted genomic and proteomic
investigations around the new millennium. The investigation of the small molecule fingerprints of HBV
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and HCV infection using metabolomics lagged behind the genomic and proteomic efforts by almost a
decade [8–10]. Metabolomics reveals information that is closer to the phenotype of the infected liver
than do genomics, transcriptomics, or proteomics. While these other omics might predict, to certain
degrees, the metabolic perturbations occurring post-infection with HBV or HCV, metabolomics can
give a direct measurement of these, which can then be further augmented using transcriptomic data [3].
More detailed insights can be obtained in laboratory animals [11,12] or in cell culture [13,14] by
analyzing isotopomers after the administration of [13C]glucose and/or [13C]glutamine, for example.
In human investigations, it is not possible to conduct some of these procedures. Ex vivo
metabolomics on urine and plasma obtained from HBV- and HCV- infected persons must rely on a
more static metabolite picture rather than the dynamic metabolism of isotopomers. Although several
investigators have reported metabolomic data on HBV and HCV patients, investigations were in
general conducted to discover biomarkers for HBV [10,15,16] and HCV [15,17–19] cirrhosis or fibrosis,
together with HCC metabolism with HBV [1,15,20] and HCV [3,15,21] infection or for progression to
HCC [22–26]. Studies have also simply investigated the impact of HBV [27–30] or HCV [8,27,31–33]
infection on the metabolome or the metabolic consequences of drug treatment [2,34,35].
Many metabolomics reports, particularly the earlier ones, merely generate a list of up- and
down-regulated metabolites in one condition versus another. It is important that metabolomic findings
lead to mechanistic insights. For example, we described a metabolomic investigation of HCV infection
using matched uninfected controls. The finding of downregulated urinary fructose and galactose
combined with upregulated urinary sorbitol, galactitol, and xylitol led to the finding that the aldose
reductase gene AKR1B10 displayed a six-fold increased expression in HCV+ compared to HCV- liver
biopsies [36]. This increased flux through the polyol pathway consumes NADPH, the obligatory
cofactor in the generation of antioxidant GSH by glutathione reductase [37], and therefore is likely
to contribute to elevated ROS and therefore to HCV hepatitis [36]. Gas chromatography-mass
spectrometry (GCMS) is particularly adept at the detection and quantitation of small intermediary
metabolites such as those comprising glycolysis [36], the TCA cycle [38], and the pentose phosphate
pathway [39]. Robust bioinformatic procedures are required to identify the maximum number of
metabolic networks that might be up- or down- regulated in particular biological circumstances,
based upon urinary and plasma/serum GCMS metabolic profiles. In this report, we used regression
analysis and revealed many changes in the correlations of metabolite pairs, indicating subtle differences
between the metabolomes of HBV and HCV infected patients.
2. Results
2.1. Direct Comparison of Metabolite Intensities Shows Very Little Difference between HBV and HCV Patients
We expanded the previously reported GCMS dataset of 30 HCV patients with an additional
30 HBV patients. For each patient, we analyzed both a blood plasma and a urine sample. The same
control plasma and urine donors were used for both datasets. Both datasets were merged and corrected
for batch effects (see Materials and Methods). After excluding patients that had resolved the infection
and outlier samples, our dataset contained data from 27 HBV patients, 19 HCV patients, and 26 healthy
control subjects.
To account for the batch effect, we only included metabolites that were positively detected in
both datasets, either in the control or patient samples, separately for each biofluid, namely, plasma or
urine. In other words, metabolites detected only in one dataset were excluded from further analysis.
It should be noted that, whenever a metabolite was observed in a given dataset, it was always detected
in both the patient and control subjects. Thus, our analysis did not detect any metabolites that are
unique to HBV or HCV infected patients. Table 1 lists the retained metabolites for both body fluids.
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Table 1. List of metabolites included in the merged dataset.
Metabolite RT (min) Plasma Urine
lactic acid 13.32 X X
glycolic acid 13.80 - X
p-cresol 16.36 - X
valine 19.28 X -
urea 20.20 X -
ethanolamine 21.05 X -
leucine 21.24 X -
isoleucine 21.98 X -
proline 22.08 X -
glycine 22.42 X X
serine 24.30 X X
threonine 25.21 X X
threitol 28.38 - X
erythronic acid 29.73 - X
threonic acid 30.79 - X
ribose *
30.97
33.29
33.71
- X
4-hydroxyphenylacetic acid 32.10 - X
xylitol 34.56 - X
arabitol 34.90 - X
fucose 35.06 - X
citric acid 37.95 - X
HPHPA ** 37.96 - X
myristic acid 38.11 X -
gluconolactone 39.15 - X
fructose 39.55 - X
glucose *** 39.9240.25 X X
mannose 40.69 X -
tyrosine 40.79 X -
mannitol 41.02 - X
gluconic acid 42.20 - X
palmitoleic acid 42.46 X -
mucic acid 42.54 - X
scyllo-inositol 42.76 - X
myo-inositol 44.78 X X
oleic acid 46.80 X -
stearic acid 47.33 X -
oleamide 50.53 X -
sucrose 53.72 - X
cholesterol 61.47 X -
* Ribose runs as three peaks due to an unmethoxymated silyl derivative, together with the (E)-and (Z)-isomers of
the O-methyloxime silyl derivative of the ribose aldehyde. ** 3-(3-Hydroxyphenyl)-3-hydroxypropionic acid, a gut
microbiota metabolite produced by Clostridia spp. from phenylalanine and related to autism and schizophrenia, as
are 4-hydroxyphenylacetic acid and p-cresol, also observed in hepatitis B virus (HBV) and hepatitis C virus (HCV)
patient urine (see above) [40,41]. *** Glucose runs as two peaks due to the (E)- and (Z)-isomers of the O-methyloxime
silyl derivative produced by derivatization of the glucose aldehyde. RT means retention time (min).
As can be seen from the principal component analysis (PCA) plots in Figure 1, the metabolomic
profiles of the urine samples (left panel) of the three sub-cohorts (control, HBV, and HCV) all cluster
together. The control plasma samples (right panel) are somewhat separated from both the HBV and
HCV samples, mainly along the second component (PC2). However, although the HBV samples seem
to have a larger spread along PC1, the HBV and HCV plasma samples also separate quite poorly. Thus,
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the PCA suggests that there seems to be very little difference between the metabolomic profiles of HBV
and HCV patients.
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Figure 1. Principal component analysis (PCA) for the urine and plasma datasets.
This observation is also confirmed when we look at the difference in intensities of individual
metabolites. Figure 2 shows dot and boxplots for all metabolites that had statistically significantly
different intensities between any of the three sub-cohorts. In total, we found 20 significant metabolites
with an adjusted p value of 0.05 or less. Of those, 10 were different between HBV patients and the
control samples and 17 ere different between HCV patients and controls. Only one compound,
urinary glycolic cid, was found to be statistically si nificantly different betwe n HBV and HCV
patients, with an adjusted p value of 0.022. I was also gre ter in HBV (+7%) and lesser in HCV
(−2%) than in the co trols. Two m tabolites, urine citric cid (+8%) nd urine mucic a id (+6%), only
had higher intensities in HBV compared to the controls, whereas three metabolites, plasma glucose
(+10%), plasma mannose (+13%), and plasma palmitoleic acid (+44%), only had higher intensities
in HCV compared to the controls. Four metabolites were found to be elevated in both HBV and
HCV: plasma oleamide (+300%, +260%, respectively), urine fucose (+8%, +8%, respectively), plasma
oleic acid (+6%, +5%, respectively), and urine xylitol (+11%, +14%, respectively). No metabolite
was found to have lower intensities in HBV only, but seven metabolites were di inished in HCV
compared to the controls: plasma lactic acid (−23%), plasma valine (−3%), plasma leucine (−4%),
plasma proline (−6%), urine scyllo-inositol (−5%), urine myo-inositol 7 ), and urine mannitol
(−13%). Finally, three met bolites had low r lev ls in both HBV and HCV compared to the controls:
plasma myo-inositol (−9%, −10%, respectively), plasma isoleucine (−7%, −4%, respectively), and
urine fructose (−15%, −10%, respectively). The respective p values are given in Figure 2. We had
previously reported some of these differences between HCV and the controls in a separate study [36].
In summary, HBV plasma differed statistically significantly from the control plasma, mainly due to
an increase in the lipids oleamide and oleic acid. HCV plasma, similarly, differed from the control
plasma with increased lipids (oleamide, palmitoleic acid, and oleic acid); increased sugars, namely,
glucose and mannose; decreased lactic acid; and decreased amino acids, namely, proline and the
essential branched-chain amino acids (BCAAs), valine, leucine, and isoleucine. HBV and HCV urinary
metabolite patterns were more similar to those for plasma (Figure 2).
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Figure 2. Dot and boxplots for the metabolites with statistically significantly different intensities
between the three sub-c horts. The p values re adjusted for multip e compariso s (Benjami i-Hochberg).
2.2. Regression Analysis Reveals Different Metabolite Correlation Patterns between HBV and HCV Patients
After directly comparing the metabolite intensities, we next constructed metabolic perturbation
networks for both HBV and HCV. These networks are based on the observation that, for some
metabolite pairs, the correlation of their intensities changes between the different sub-cohorts in our
dataset. Figure 3 gives such an example. As can be seen from this figure, no correlation is observed for
the control cohorts (marked as ‘none’ in the legend), nor for the HBV patients. A negative correlation,
however, can be observed for the HCV cohort. This observation suggests that a metabolomic process
involving both of these compounds is at play in HCV patients, which is otherwise absent in control
individuals as well as in HBV patients.
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(regression line and 95% confidence interval shown) is statistically significant.
To inv stig te to the glo al extent of this phen meno , we used robust linea regression models
to detect all pairs of metabolites where the correlation pattern changes between the control cohort and
either the HBV or HCV patients (see Materials and Methods). We then summarized all these cases into
a disease-specific metabolic perturbation network for each virus. In these networks, the nodes represent
metabolite and the edg s represent the c rrelation patt rns between them. We discriminate between
four different types of edges. The first type is called ‘appear’ and refers to cases in which no correlation
is observed in the control group but one appears in the virus group. Likewise, the ‘disappear’ type
represents cases in ich an bservation i present in the control group but disappears in the virus
group. Additio ally, we als define the ‘flip’ typ , which occurs when a positive correlati is observed
in one group and a negative one in the other. Finally, we also consider ‘change’ relations, which denote
the cases in which the slope of the regression line changes significantly between both groups, without
affecting th sign—positive or n gative—of the correlation. See the Materials and Methods s ction for
a description of how thes types are determin d statistically.
Figure 4 shows the resulting metabolic perturbation networks for HBV and HCV in plasma and
urine. Surprisingly, the vast majority of edges are of the ‘appear’ type, as listed in Table 2. For both
networks together, 28 ‘appear’ edges were found, compared to only three ‘flip’ edges, and no ‘change’
or ‘disappear’ edges. Another striking observation is that, for both HBV and HCV, the metabolic
perturbation networks are much bigger in plasma compared to urine. Indeed, taken together over
both virus types, we detected 23 perturbation edges in plasma compared to eight in urine, which is a
statistically significant difference (χ2-test; p = 0.0071).
When totaling the number of perturbations across virus types, it can be seen that the HCV network
is bigger, with 20 edges compared to only 11 edges in the HBV network. Although this difference is not
statistically significant (χ2-test; p = 0.11), it is still remarkable, given that we included only 19 HCV
patients in our analysis, compared to 27 HBV patients, which would actually reduce the statistical
power to detect correlations in the HCV cohort.
From a qualitative point of view, it is striking that the metabolic perturbation networks of HBV
and HCV are fairly similar in plasma, sharing seven nodes, whereas the urine networks only have
two metabolites in common (Figure 4). Indeed, the HBV and HCV plasma networks have a common
‘backbone’ of an edge between serine and isoleucine, as well as most of the edges connected to the
latter two nodes. The only unique features of the HBV plasma metabolic perturbation network are the
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‘flip’ edge between valine and glucose and the ‘appear’ edge between isoleucine and palmitoleic acid.
Interestingly, the nodes unique to the HCV network are related to the lipid metabolism, apart from
mannose and glycine. Ethanolamine and myo-inositol are head-groups of phospholipids; myristic acid
and oleamide are, respectively, a saturated and a monounsaturated fatty acid; and cholesterol is a key
lipid. The urine networks only share two nodes, glucose and threonic acid. Although both nodes are
connected by an ‘appear’ edge in both networks, the sign of the correlation is opposite between HBV
and HCV.Metabolites 2017, 7, 51 7 of 22 
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Table 2. Counts of the different edge types for the metabolic perturbation networks of each virus in
each fluid.
Appear Flip
HBV
plasma 8 1
urine 2 0
HCV
plasma 13 1
urine 5 1
2.3. Mechanistic Interpretations of the Metabolic Perturbation Networks
2.3.1. General Considerations
It should be recalled that the PCA plots for both the plas a nd urine dat sets sho ed clustering
of the HBV, HCV, and control dat suggesting little, if any, differ nce in the plasma and urine
metabolomes for any of the three datasets (Figur 1). However, of the 39 metabolite (T ble 1) included
in the analysis, 20 showed statistically significa t differences between the HBV, HCV, and control
datasets. Furt ermore, the robust regression analysis, involving 490 regressions, 190 for the plasma
metabolites and 300 for the urinary metabolites, produced the metabolic perturbation networks in
Figure 4.
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The first approach to understanding the binary metabolite relationships described by the
perturbation networks was to create a metabolic network by retrieving all human enzyme-substrate
and enzyme-product relations from the KEGG database. For each pair of metabolites connected by
an edge in a metabolic perturbation network, we then detected all the shortest paths between these
in the metabolic network. We then compared the number of times each node or edge occurs in these
shortest paths to the same number in randomized networks (see Materials and Methods) to obtain,
for each metabolic perturbation network, a statistically significant metabolic network (Appendix A).
Figures A1 and A2 show these metabolic networks for urine and plasma, respectively. It was found
that this approach resulted in a complex outcome that was difficult to interpret. It was therefore
decided to proceed using the published literature to interpret the positive and negative correlations in
plasma and in urine for both HBV and HCV.
2.3.2. Analysis of the HBV and HCV Metabolic Perturbation Networks
As can be seen in Figure 4a, the central node of the HBV plasma network is isoleucine, which
is connected to oleic acid, palmitoleic acid, threonine, proline, and serine, the last of which is a
node connected to valine and leucine and then to glucose. Interestingly, the edges connecting
isoleucine to other amino acids (threonine, serine, proline) all consist of positive correlations, while
the connections to the two monounsaturated fatty acids (MUFAs), oleic acid and palmitoleic acid,
represent negative correlations. The oleic acid-isoleucine negative correlation (Figure 4a) is consistent
with the observations that plasma oleic acid was greater in HBV than in the controls and that plasma
isoleucine was lower in HBV than in the controls (Figure 2).
The HBV urine network is comprised of just two correlations, a negative correlation between
gluconolactone and xylitol and a positive correlation between glucose and threonic acid (Figure 4c).
All four of these cellular metabolites have relationships to the pentose phosphate pathway (PPP).
Glucose and xylitol feed the PPP through glucose-6-phosphate and xylulose/xylulose-5-phosphate,
respectively [42]. Gluconolactone and threonic acid are metabolites produced by the PPP from glucose
and xylitol, respectively [42].
The HCV metabolic perturbation networks contain more correlations than their HBV counterparts
(Figure 4b,d). The central node in the HCV plasma network (Figure 4b) is serine, which is connected
directly to the three BCAAs, leucine, isoleucine, and valine (positive correlations), and also to
myo-inositol (negative correlation). Leucine is negatively correlated with valine but positively
correlated with threonine. Other negative correlations in HCV plasma worthy of note are between
valine and cholesterol, isoleucine with oleic acid (common to HBV plasma; Figure 4a), and glycine
with ethanolamine. In this last case, serine is decarboxylated to ethanolamine, leading in two further
steps to glycolic acid, whereas glycine is transaminated to glyoxylic acid, which is reduced to glycolic
acid. The negative correlation between glycine and ethanolamine would be explained by fluxes in
these pathways, especially as glycine and serine are metabolically interchangeable [43].
The urinary ribose and citrate negative correlation (Figure 4d) may be a direct effect of the HCV
virus. It has been reported that monocyte derived macrophages infected with HIV-1 or HIV-2 displayed
elevated ribose 5-phosphate, a PPP intermediate, with no change in TCA cycle intermediates such
as citrate when compared with noninfected cells [44]. Citric acid was also negatively correlated with
L-erythronic acid ((2R,3R)-2,3,4-trihydroxybutanoic acid), the diastereomer of threonic acid [45], in the
HCV urinary network (Figure 4d). In summary:
• The initial PCA analysis of plasma and urine datasets suggested that there were few differences
between the HBV+, HCV+, and control metabolomes.
• Univariate statistics gave 28 statistically significant differences for a subset of 20 metabolites; 15 in
plasma and 13 in urine.
• Robust regression analysis revealed networks of correlations between pairs of metabolites that
mainly appear in HBV+ and HCV+ plasma and urine but are not observed in healthy controls.
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• The positive and negative correlations provided novel insights into the HBV+ liver compared
with the HCV+ liver.
3. Discussion
Multiple metabolomic studies on HBV+ and HCV+ patients have been reported. For HBV,
the studies mostly sought biomarkers of the development of cirrhosis or HCC [24,46–49] or biomarkers
simply of HBV infection itself [10,28]. Similar studies have been reported in the case of HCV for
serum biomarkers of progression to HCC [21–23] and for hepatic fibrosis [17,19]. Since HCV infection
can be treated, several reports deal with metabolomic changes before and after treatment that were
interpreted as reflecting the metabolic effects of the virus [2,34]. Finally, urine analysis by NMR has
been proposed as a means of early detection of HCV infection [8].
In contrast to the aforementioned studies, ours was the first to compare HBV+ with HCV+
patients, together with uninfected healthy controls. Furthermore, both plasma and urine were analyzed.
Our aim was to understand the differential footprints of HBV and HCV on the liver by uncovering the
covariation between metabolites. Therefore, a direct comparison between the two viral infections was
made using the same control group of healthy subjects. It was not our objective to discover biomarkers
for HBV and HCV infection, as the literature is replete with such data. Our intention was to tease out
statistically significant correlations, both positive and negative, between pairs of metabolites to create
what we have called ‘metabolic perturbation networks’. To generate metabolic perturbation networks,
we conducted a robust regression analysis for both plasma and urinary metabolites, involving 490
regressions. ‘Perturbation’ refers to the fact that some correlations appeared in, say, HBV or HCV
patients that were not present in the controls, and a few flipped their correlation from positive
to negative between HBV and HCV patients. Using this analysis, it was believed that metabolic
differences between the HBV-infected and the HCV-infected liver could be identified.
It is pertinent to discuss whether or not the differences between HBV and HCV patients, together
with the metabolite correlations we observed, could be due to spurious factors. Firstly, bloods were
collected from all patients, according to a standardized protocol in the hepatology clinic, and the plasma
was quickly prepared and frozen at -80◦C. Furthermore, all patients were fasted for a minimum of 6 h.
The samples were analyzed by GCMS using the same laboratory procedure for all batches, run on the
same instrument and by the same analyst. However, the HBV patients were statistically significantly
younger than the HCV patients, with significantly lower plasma ALT values. These observations
with age and ALT were not unexpected, for they have been reported by others in a large European
study [50]. Moreover, a positive smoking history and current use of medication were statistically
significantly more common in HCV patients than in HBV patients. However, the occurrence of diabetes,
fasting blood glucose levels, and BMI values did not differ statistically between the two patient groups.
Therefore, we do not believe that dietary factors or host metabolic factors contributed significantly to
the metabolic findings that are ascribed here to chronic HBV or HCV infection. Furthermore, the stage
of hepatic fibrosis as determined by the METAVIR score was not statistically significantly different
between HBV (2.1 ± 1.4) and HCV (3.1 ± 0.9) patients and therefore did not appear to be related to the
metabolic findings presented here.
Amino acids are a source of cellular energy by the anaplerotic feeding of the TCA cycle via
intermediates such as pyruvate, 2-oxoglutarate, and succinyl-CoA [51], which may explain the
multiple correlations in plasma amino acid concentrations reported for fasted patients [52]. Moreover,
HBV appears to elevate amino acid levels in concert in hepatocytes [29], perhaps explaining the
positive amino acid correlations described here for HBV plasma (Figure 4a). Finally, branched-chain
amino acids (BCAAs), particularly leucine but also isoleucine and valine, regulate protein translation
and, therefore, amino acid levels, involving mTORC1 activation [53] by the HBV HBx protein [54].
In addition, HBx has been shown to activate fatty acid oxidation [55], fueling the TCA cycle with
increased acetyl-CoA and thus will decrease the demand on amino acid anaplerosis. This may explain
the negative correlations of HBV plasma for isoleucine with both oleic acid and palmitoleic acid.
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Regarding xylitol in the urine of HBV patients, this polyol was found to exhibit the largest
decline of any urinary metabolite detected between control samples and liver cirrhosis/hepatocellular
carcinoma patients in Egypt [56]. Furthermore, it was reported over four decades ago that patients
infused with xylitol showed grossly increased urinary excretion of threonic acid, interpreted as arising
through the PPP [42,43]. In addition, L-threonic acid ((2R,3S)-2,3,4-trihydroxybutanoic acid) is also an
oxidative metabolite of ascorbic acid formed via dehydroascorbic acid (DHA) [57,58] that is believed
to be transported into cells by glucose transporters that also transport DHA [59]. Therefore, the
cotransport of glucose and threonic acid may also explain the positive correlation between these two
metabolites in HBV urine or, in addition, the conversion of glucose through the PPP to yield threonic
acid [42,43]. It has also recently been suggested that elevated threonic acid, as an oxidative metabolite
of ascorbic acid, is a measure of an attenuated oxidative stress response [60].
As stated above, the only metabolite that was statistically significantly different between HBV
and HCV was urinary glycolic acid (Figure 2), reflecting differential glycine and serine metabolism
between these two virus infections. Concerning the leucine and valine negative correlation, mild liver
damage caused by the administration of 2 g CCl4 to rats resulted in a rise in plasma valine and a fall
in plasma leucine 16 h post-administration. With 4 g and 8 g doses, more severe liver damage was
recorded, together with rises in most plasma amino acids [61]. HCV hepatitis may mimic these amino
acid changes. Regarding the valine and cholesterol negative correlation in HCV plasma, metabolic
syndrome was reported to be distinguished from obesity by increased valine, leucine, and isoleucine
degradation [62]. Both conditions are associated with elevated serum cholesterol. Furthermore,
rats fed a diet supplemented with BCAAs and had no change in serum total cholesterol but displayed
a lower hepatic cholesterol deposition [63]. Finally, since cholesterol and BCAAs are potential energy
metabolites, it is reasonable that their plasma levels might be negatively correlated. Both serine and
myo-inositol are components of relatively minor membrane phospholipids. Myo-inositol is incorporated
directly into phosphatidylinositol in the endoplasmic reticulum (ER). Phosphatidylserine is synthesized
from phosphatidylcholine or phosphatidylethanolamine, also in the ER [64]. However, there is
competition between serine and myo-inositol for the pathways that lead to these phospholipids [64,65],
perhaps explaining their negative correlation in HCV plasma. We have previously reported that plasma
mannose is elevated in HCV+ plasma [36], and this is reflected in Figure 2. Mannose was correlated
only with threonine in HCV plasma. Protein mannosylation is a common glycosylation pattern
for HCV [66], and threonine protein residues are a principal site of mannosylation [67]. However,
it has not been reported that free threonine can be mannosylated or if the amino acid can inhibit
protein mannosylation, despite the fact that O-α-D-mannopyranosyl-L-threonine is available from
several commercial sources. This would have furnished an explanation for the negative correlation
between mannose and threonine. Finally, isoleucine and oleic acid were negatively correlated in
HCV (and also HBV) plasma. Oleic acid was higher in both HBV and HCV plasma than in control
plasma, while isoleucine was lower in both HBV and HCV plasma than in control plasma (Figure 2).
Interestingly, a rat model for postoperative fatigue syndrome, involving both 30% and 70% partial
hepatectomies, displayed a progressive declining trend from control to 30% hepatectomy to 70%
hepatectomy for a number of serum metabolites, including isoleucine. Concomitantly, there was an
increasing trend across the same samples for several other metabolites, including oleic acid [68]. One
possible explanation for the decline in plasma isoleucine, a BCAA, is that it is used as an energy source,
as has been reported for fatigued human subjects [69]. Under such circumstances, increased fatty
acid mobilization may occur as a potential energy source, explaining the rise in plasma oleic acid [68].
This would also suggest that both HCV+ and HBV+ patients behave metabolically like patients with
postoperative fatigue syndrome.
Regarding the positive correlation between citric acid and erythronic acid in HCV urine
(Figure 4d), the literature gives little guidance on this, except that both were uncorrelated in the
plasma of patients with acute ischemic stroke [70] and that urinary erythronic acid was massively
elevated in the transaldolase deficiency of the PPP. In this ischemic stroke study, citric acid was not
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measured, but two additional TCA metabolites, 2-oxoglutarate and fumarate, were also massively
increased in urine [45]. Finally, erythronic acid was one of three upregulated metabolites in both
plasma and urine in response to a single oral dose of either 50 or 100 g sucrose [71]. It is believed
that erythronic acid is increased when there is diminished flux through the PPP, as in the case of
transaldolase deficiency [45]. Erythronic acid has therefore been proposed to be generated by an as yet
unknown alternative pathway to the PPP [45,71]. This as yet undescribed pathway may be related to
the TCA cycle since erythronic acid was negatively correlated with citric acid in HCV urine (Figure 4d).
While the PPP appeared active in HBV liver, the data suggest that it may be impaired in HCV liver.
The negative correlation between urinary mucic acid and threonic acid in HCV is also of interest
(Figure 4d). Mucic acid is the dicarboxylic acid of galactose and can be fermented by several species of
the intestinal microbiota such as Escherichia coli and Salmonella enteritidis [72]. Threonic acid is elevated
in the serum of mice with experimental intestinal ischemia [73], which may have been the result of
altered gut floral metabolism. This negative correlation in HCV may result from alterations in the
intestinal microbiota metabolism. As indicated above, we report a positive correlation between
threonic acid and glucose in HBV urine (Figure 4c), but, in HCV urine, a negative correlation
was found for these two metabolites (Figure 4), a clear distinguishing metabolic feature between
HBV and HCV hepatitis. This observation in HCV is a similar finding to the changes found in
intestinal ischemia in mice [73]. HCV+ patients tend to be hyperglycemic, as shown in Figure 2
and as has been discussed elsewhere [36]. Glucose transport may underlie the relationship between
glucose and threonic acid. The question, therefore, is whether or not glucose transporters operate
differently in HBV+ and HCV+ livers. In the case of HBV, the deletion mutant pre-S2 protein is
capable of activating the mTOR signal cascade [74], which leads to the translocation of the SLC2A1
(GLUT1) transporter protein to the hepatocyte membrane, enhanced cellular glucose uptake, and
aerobic glycolysis (‘Warburg effect’) [75]. By contrast, the HCV NS5A protein promotes hepatic
gluconeogenesis [76] through phosphoenolpyruvate carboxykinase (PEPCK), which is in part regulated
by the energy metabolism of the TCA cycle [77,78]. NS5A also suppresses the membrane expression of
the SLC2A1 and SLC2A2 (GLUT2) transporters and therefore glucose uptake into liver [76,79]. These
mechanisms are believed to contribute to the hyperglycemia frequently associated with HCV infection,
at least for HCV genotype 3 [80]. Moreover, the polyol pathway is upregulated by HCV, whereby
glucose is reduced to sorbitol by aldose reductase AKR1B10, which is then oxidized by sorbitol
dehydrogenase to fructose [36]. NADPH is exchanged for NADH in this pathway, which compromises
NADPH-dependent reactions such as glutathione reductase and nitric oxide synthase [37]. These
differential mechanisms of glucose homeostasis may underpin the divergent correlations of glucose
with threonic acid and glucose with fructose in HBV and HCV urines.
This analysis is consistent with the HBV+ liver importing glucose via the SLC2A1 and SLC2A2
transporters and activating glycolysis and PPP but attenuating the TCA cycle. In comparison, this
analysis is consistent with the HCV+ liver not importing glucose but generating it by gluconeogenesis.
The analysis is also consistent with threonic acid being imported by the HBV+ liver using glucose
transporters and, in addition, producing by PPP as a result of xylitol metabolism. Additionally,
the analysis is consistent with glycolysis and PPP being downregulated in the HCV+ liver, with a
consequent decrease in plasma lactic acid, and is also consistent with intracellular glucose leaking from
the cell and contributing to the hyperglycemia frequently observed with chronic HCV infection. Finally,
the analysis is consistent with the BCAAs valine, leucine, and isoleucine being metabolized in the HCV+
liver via the TCA cycle, thus lowering their plasma concentrations and bolstering gluconeogenesis.
Our bioinformatic investigation of the GCMS data resulting from the analysis of plasma and
urine samples from HBV+ and HCV+ patients, together with HBV- and HCV- controls, has produced
divergent metabolic pictures of the HBV and HCV infected liver. In the case of HBV infection,
it could be interpreted that glucose was actively imported and used to fuel glycolysis and the PPP.
In the case of HCV infection, the liver appeared not to import glucose but rather to synthesize it
by gluconeogenesis using TCA cycle intermediates in part derived from BCAAs. We derive these
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interpretations using the following published observations. Our plasma analyses revealed that all
three BCAAs were statistically significantly depressed in HCV+ patients. We have interpreted this as
enhanced anaplerosis, which helps to fuel gluconeogenesis. After several catabolic steps, both leucine
and isoleucine enter the TCA cycle as acetyl-CoA, and valine enters via succinyl-CoA. The expression
of all the genes that regulate the rate-limiting steps of BCAA catabolism (BCAT2, DBT, DLD, BCKDHA,
and BCKDHB) is correlated with insulin sensitivity [81]. HCV infection has long been recognized
as being associated with type 2 diabetes mellitus (T2DM) [82], and a mouse model expressing the
full HCV ORF has recently established that impaired glucose metabolism is a probable cause [83].
Of note was that this mouse model had reduced the hepatocyte membrane expression of SLC2A2
and displayed an attenuated uptake of glucose and higher hepatic glucose production. These data
are consistent with our metabolomic findings, described above. The combination of reduced glucose
uptake and impaired insulin signaling in these HCV protein expressing mice was interpreted as the
cause of insulin resistance [83]. Given the effects of BCAA catabolism on insulin sensitivity [81], what
role might BCAAs play in reversing insulin resistance? Several clinical investigators have administered
BCAAs to HCV infected patients in attempts to improve prognosis [84]. This area is controversial, with
some commentators suggesting that BCAAs can activate mTORC1 and cause insulin resistance [85],
despite the observed beneficial effects to HCV infected patients of BCAA supplements or a BCAA-rich
diet [84,86]. These relationships between BCAAs, gluconeogenesis, and hyperglycemia in HCV patients
are implicit in our metabolomic model, described herein.
In general, metabolomic investigations using case-control protocols for diseases such as viral
hepatitis have produced lists of latent biomarkers that have then been subjected to receiver
operating characteristic (ROC) curve analysis to evaluate their suitability as classifiers (for example,
the progression of hepatitis [24] or cirrhosis [46] to HCC or distinguishing between different
grades of HCC [33]). Furthermore, metabolite set enrichment analysis has been reported
in metabolomic studies of this kind, which use, for example, the MetaboAnalyst 3.0 online
algorithm (http://www.metaboanalyst.ca) [87,88]. Groups of discovered metabolites are often placed
schematically into boxes labeled, for example, phospholipid metabolism, long-chain fatty acids, or
steroid biosynthesis [87]. In addition, some studies have undertaken network analysis, the stringing
together of the observed list of elevated metabolites in a disease state into an annotated network that
contains cognate biochemical pathways [16,24]. However, these are merely graphical representations
of a metabolite list, enhanced or attenuated in a particular state.
We have taken a different approach. Plasma and urine metabolites are not always the products of
metabolic pathways or their substrates. They may be elevated or reduced in these biofluids as a result of
alterations in membrane transporters due or in some other way related to the disease state. Moreover,
a metabolite may not be acting merely as an enzyme substrate; it may inhibit another pathway
competitively or noncompetitively. In addition, non-peptide neurotransmitters may be discovered by
metabolomics in plasma or urine in various disease states, and, therefore, the appearance of molecules
such as acetylcholine or norepinephrine would most likely to be due to neuronal activity rather than
direct biosynthesis. The approach described here, that is, using robust regression analysis to generate
metabolic perturbation networks, sought to uncover correlations, both positive and negative, between
pairs of metabolites in both HBV and HCV infected persons. Rather than a list, these metabolic
perturbation networks point clearly to the differential metabolic rewiring in HBV and HCV infection,
as reported here.
4. Materials and Methods
4.1. Patient Selection
We created a combined HBV and HCV patient cohort by complementing the HCV cohort from our
previous study [36] with a new HBV cohort. In both cases, the patients were positive for the respective
virus but had not developed liver cirrhosis (LC) or HCC. In total, our combined cohort consisted of
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30 HBV patients and 30 HCV patients chosen from the Bern Hepatology Biobank. All gave their written
informed consent to donate blood and urine to the biobank, and the study was conducted according to
the World Medical Association Declaration of Helsinki. The clinical investigation of HBV and HCV
patient material was approved by the Ethics Commission of the Canton of Bern (Die Ethikkommission
des Kantons Bern; reference number KEK 141/14). The HBV group consisted of 16 women and 14 men;
the HCV group consisted of 15 women and 15 men. The patient age in the HBV group ranged from
20 to 66 years, with a mean (±S.D.) age of 40.6 ± 10.5 years, and, in the HCV group, it ranged from
28 to 73 years, with a mean of 50.0 ± 11.1 years (p < 0.01). For the HBV and HCV patients, the average
BMIs (Kg/m2) were 26.1 ± 5.2 and 25.0 ± 5.2 (n.s.), respectively. For the HBV and HCV patients,
the fasting blood glucose levels were 5.3 ± 1.4 and 5.0 ± 0.7 (n.s.), respectively, the plasma alanine
aminotransferase levels (ALT; IU/l) were 49.9 ± 58.2 and 87.2 ± 62.1 (p < 0.01), respectively, and the
METAVIR staging (degree of fibrosis) was 2.1 ± 1.4 and 3.1 ± 0.9 (n.s.), respectively. Diabetes had
been diagnosed for three of 30 patients in both groups. A smoking history was determined for seven
of 30 HBV and 23 of 30 HCV patients (χ2 = 17.1; p < 0.0001), and medication was taken by seven of
30 HBV and 20 of 30 HCV patients (χ2 = 11.4; p < 0.001). For this study, we excluded one HBV and
six HCV patients that had resolved the infection, either spontaneously or after antiviral therapy.
For each patient, both a urine and a blood plasma sample was taken from the biobank for
metabolomic profiling. The blood had been collected into EDTA tubes after a minimum of a 6 h
fast, and, according to strict protocol in the hepatology clinic of the Inselspital Teaching Hospital, the
plasma was prepared within 30 min and stored at −80 ◦C. Additionally, we used the same collection
of control samples that were previously described [36]. This collection consisted of 30 urine samples
from healthy volunteers (15 F, 15 M; aged 18 to 63 years), who were staff in the university and hospital
departments, as well as 30 plasma samples from the local blood bank, from voluntary blood donors
from all over Switzerland (15 F, 15 M; aged 41 to 55 years). All samples tested negative for the presence
of antibodies and/or antigens for HIV, HCV, and HBV. All samples were also negative for syphilis.
HIV, HBV, and HCV PCR testing was also negative for all control samples.
4.2. Gas Chromatography-Mass Spectrometry (GCMS) Analysis of Plasma and Urine
For the HBV, HCV, and control cohorts, both plasma and urine were profiled on the same GCMS
instrument by the same operator after double derivatization and using 4-chlorophenylacetic acid
as internal standard, as described [36,39,73,89]. Annotation of the gas chromatographic peaks was
made upon both comparisons of the mass spectra with the NIST 14 library spectra collection of 276,
248 mass spectra and comparisons of the retention times and mass spectra of an in-house collection of
120 authentic compounds, as described previously [39,89].
4.3. Data Processing, Batch Correction, and Integration
For each patient cohort, HBV and HCV, and each sample type, urine and plasma, a separate
dataset was created, consisting of patient and control samples. In each dataset, the relative intensities
were processed as follows:
1. A matrix I was constructed in which the columns represent the samples and the rows the
measured metabolites
2. A floor value, f , was calculated as f = blog2
(
Ii,j
)c for all elements Ii,j of I, where Ii,j > 0
3. All elements of I, where Ii,j = 0, are assigned a value of 2 f
4. The entire matrix is now transformed such that I′ = log2(I)− f
5. A vector, m, is calculated as the column means of I′, as well as a vector, s, as the column standard
deviations. A vector, o, is defined as o = m−min(m)
6. The vector, o, is subtracted from each row of I′
7. Each row of I′ is divided by s
8. Finally, all values of I′ are offset by a value such that the lowest value of I is zero.
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9. The result of these operations is a matrix in which all columns have the same mean and
standard deviation.
The replicate samples—columns in the matrix I′—are averaged in order to obtain a final intensity
matrix, J, with as many columns as subjects, both patients and controls, in the cohort.
For each sample type, the matrices JHBV and JHCV are merged by first identifying the set of
compounds C that were identified in both datasets. A merged matrix, M, is then created by selecting
from JHBV and JHCV those rows that correspond to the compounds in C and by concatenating the
columns of both sub-matrices. The resulting matrix is then batch-corrected using the method described
by Leek et al. [90]. This step results in two single matrices, Mplasma, containing data for 20 metabolites,
and Murine, containing 25 metabolites.
Finally, Mplasma and Murine are merged into one big matrix, Mmerged, by concatenating their rows.
This matrix is then used for all subsequent analyses and will from here on simply be referred to as M.
4.4. Detection of Differentially Abundant Metabolites
Metabolites that have statistically significant different abundances between two sample groups
were detected using an unpaired t test. The resulting p-values were corrected for multiple testing
using the Benjamini-Hochberg method.
4.5. Robust Regression Analysis
For each pair of metabolites X, Y, i.e., each pair of rows in the matrix M, five different robust linear
models are fitted, each corresponding to a different scenario about how the intensity of Y, denoted as
y, correlates to the intensity of X, denoted as x, as well as the patient group g:
1. A null model, with a single intercept, representing the case that y is independent of both x and g.
2. An intercept-only model, with a different intercept per subject group, modelling the case that y
only varies with g.
3. A single intercept, single slope model, for the case in which y only correlates with x and is
independent of g
4. A multiple intercept, single slope model, representing the case in which y depends on both x and
g but in which the slope does not vary between the different patient groups.
5. An interaction model, where y depends on both x and g, as well as the interaction between them,
meaning that the slope changes between the patient groups.
For both the multiple intercept and the interaction models, the reference for both the intercept
and the interaction terms is the control cohort. As a result, the interaction terms reflect the difference
between the regression slope coefficients of the HBV and HCV patients and the control subjects.
The models were fitted using the rlm function from the MASS package in R [91]. Akaike’s information
criterion (AIC) [27] was then used to determine which of these models fit the data best. Each time the
interaction model had the best fit, a Wald test was used to calculate the significance of the interaction
terms of this model. In all other cases, the p-value was assumed to be 1. The p-values for all models
were then corrected for multiple testing using the Benjamini-Hochberg method.
All models with an adjusted p-value of 0.01 or less were retained. For each model, 95% confidence
intervals were constructed for the general slope coefficient and the interaction terms for both HBV
and HCV. Whenever this interval included zero, the corresponding coefficient was set to zero. Next,
for each virus type, a network was constructed in which the nodes represent metabolites and the edges
the models describing the correlation between them. Depending on the values of the general slope
coefficient and the interaction coefficients for the respective virus, the edges were assigned to one of
these types:
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• When the interaction coefficient for the virus was zero, the edge was not included in the network.
• When the general slope was zero but the interaction coefficient was different from zero, the edge
type was called ‘appear’
• When the general slope was different from zero but the interaction coefficient was zero, the edge
type was called ‘disappear’
• When the both the general slope and the interaction coefficient were different from zero and the
slope of the HBV or HCV patient group had a different sign than the general slope, the edge type
was called ‘flip’. Note that the slope of a patient group is calculated as the sum of the general
slope and the interaction term.
• When both the general slope and the interaction term were different from zero, the edge type was
called ‘change’.
The resulting networks are referred to in the main text as metabolic perturbation networks.
4.6. Integration with Metabolic Networks
The collection of known human enzyme-substrate and enzyme-product annotations was retrieved
from the KEGG database using the KEGGREST R module. For enzymes with unspecific substrate
or product annotations, such as ‘a carboxylate’, specific annotations, e.g., 4-hydroxyphenylacetate,
were added manually. These annotations were then merged into a bi-partite graph in which the
nodes represented either enzymes or compounds and the edges represented substrate-enzyme or
product-enzyme relations.
This graph was then used as an undirected metabolic network to find possible metabolic
pathways between pairs of compounds found to be connected in a metabolic perturbation network.
More precisely, for every edge E connecting the metabolites X and Y in a metabolic perturbation
network, all possible shortest paths between X and Y in the metabolic network were retrieved, if any.
The output of this step is an integrated network consisting of the original metabolic perturbation
network and the metabolic shortest paths.
To assess whether the detected shortest metabolic paths are specific to the metabolic perturbation
networks, we observed artefacts caused by the presence of hub nodes in the metabolic network, and
the following Monte Carlo approach was adopted. For each node and metabolic edge in the integrated
network, an inclusion score indicating the number of times it was included in any of the metabolic
shortest paths, excluding start and end nodes, is recorded. Next, 1000 Monte Carlo replicates of the
original metabolic perturbation network are created by first randomly selecting n nodes from the
entire set of metabolites detected in our dataset and then creating the e edges between the selected
nodes, where n and e are, respectively, the number of nodes and edges in the original metabolic
perturbation network. These random networks were then integrated with the metabolic network in
the same way as the original network, and the inclusion scores for these nodes and edges were also
determined. This step allows us to compare the inclusion score of a given node or edge in the original
integrated network to its distribution of scores in the randomized networks. Applying a confidence
interval of 0.95, we consider an inclusion score in the original network to be significant if there, at most,
50 random networks with the same score or a higher score for that particular node or edge.
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